All questionsSpecific populations: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications6 questions · 2 sourcesPregnancy and breastfeedingIs Trelegy safe during pregnancy?“There are insufficient data on the use of TRELEGY ELLIPTA or its individual components, fluticasone furoate, umeclidinium, and vilanterol, in pregnant women to inform a drug-associated risk.” (opens the source at this quote in a new tab)CopyFlag“Labor or Delivery: TRELEGY ELLIPTA should be used during late gestation and labor only if the potential benefit justifies the potential for risks related to beta-agonists interfering with uterine contractility.” (opens the source at this quote in a new tab)CopyFlagCan you breastfeed while using Trelegy?“There is no information available on the presence of fluticasone furoate, umeclidinium, or vilanterol in human milk; the effects on the breastfed child; or the effects on milk production. Umeclidinium was detected in the plasma of offspring of lactating rats treated with umeclidinium, suggesting its presence in maternal milk.” (opens the source at this quote in a new tab)CopyFlagPediatric useIs Trelegy approved for children?“TRELEGY is not indicated for use in children and adolescents. The safety and efficacy in pediatric patients (aged 17 years and younger) have not been established.” (opens the source at this quote in a new tab)CopyFlagSpecific populationsIs Trelegy safe for older adults?“Based on available data, no adjustment of the dosage of TRELEGY ELLIPTA in geriatric patients is necessary, but greater sensitivity in some older individuals cannot be ruled out.” (opens the source at this quote in a new tab)CopyFlag“No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger subjects.” (opens the source at this quote in a new tab)CopyFlagNote: The second passage refers to the subjects aged 65 years and older in the label's COPD trials (Trials 1 to 3) and asthma trial (Trial 4).Can Trelegy be used with liver disease?“Use TRELEGY with caution in patients with moderate or severe hepatic impairment, as fluticasone furoate systemic exposure may increase by up to 3-fold. Monitor for corticosteroid-related side effects.” (opens the source at this quote in a new tab)CopyFlag“TRELEGY ELLIPTA has not been studied in subjects with hepatic impairment.” (opens the source at this quote in a new tab)CopyFlag“Patients with moderate hepatic impairment (Child-Pugh score of 7-9) showed no relevant increases in Cmax or AUC, nor did protein binding differ between subjects with moderate hepatic impairment and their healthy controls. Studies in subjects with severe hepatic impairment have not been performed” (opens the source at this quote in a new tab)CopyFlagNote: The third passage concerns umeclidinium.Can Trelegy be used with kidney disease?“TRELEGY ELLIPTA has not been studied in subjects with renal impairment.” (opens the source at this quote in a new tab)CopyFlag“There were no significant increases in either fluticasone furoate or vilanterol exposure in subjects with severe renal impairment (CrCl <30 mL/min) compared with healthy subjects. No dosage adjustment is required in patients with renal impairment” (opens the source at this quote in a new tab)CopyFlag“Patients with severe renal impairment (CrCl <30 mL/min) showed no relevant increases in Cmax or AUC, nor did protein binding differ between subjects with severe renal impairment and their healthy controls.” (opens the source at this quote in a new tab)CopyFlagNote: The third passage concerns umeclidinium.